Researchers at Memorial Sloan Kettering are exploring new therapies and diagnostic tools for colon and rectal cancer. If you qualify, your treatment team can recommend one of our clinical trials if they feel it may help improve your condition.

You will find two important resources here, including: 

• MSK’s Hereditary Colorectal Cancer Family Registry
• MSK’s clinical trials for colorectal cancer

Hereditary Colorectal Cancer Family Registry

MSK has established a registry for families who are affected by various types of hereditary colorectal cancer syndromes. The registry is allowing researchers to learn more about the genetic causes of colorectal cancer. It is also helping in the development of new ways to prevent, diagnose, and treat cancers of the colon and rectum.

If you enroll in the registry, you’ll be asked to complete a questionnaire about your family history of cancer. You may also have blood and tissue samples collected as part of another study. Information from these tests can be combined with data from the questionnaire to learn more about hereditary colorectal cancer syndromes. You may be contacted periodically over the next several years so that researchers can follow up on your health status.

By participating in the MSK Hereditary Colorectal Cancer Registry, you can learn more about your risk for colorectal and other cancers. The registry can also allow you to have increased surveillance if you are at risk. If you have already been diagnosed with a hereditary colorectal cancer syndrome, the registry can keep you up-to-date on new research that may affect your medical care. Our researchers are working on many projects to learn more about these syndromes. Additionally, several other studies may be open to patients enrolled in the registry.

For more information please email [email protected] or call 212-639-8278.

Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:

• 21-246 A Phase I/II Study of REGN7075 plus Cemiplimab Immunotherapy in People with Advanced Solid Tumor Cancers 
• 21-313 A Phase III Study of MRTX849 Combined with Cetuximab versus Chemotherapy in People with KRAS G12C-Mutated Advanced Colorectal Cancer that Continues to Grow 
• 19-288: Neoadjuvant PD-1 blockade in Mismatch Repair-Deficient Solid Tumors
• 12-289 ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Phase II Study of Early Post-Operative Abdominal Chemotherapy versus Heated Abdominal Chemotherapy for Cancers of the Appendix, Colon, or Rectum that Have Spread to the Abdominal Lining 
• 22-438 A Phase II Study Assessing the Addition of Irinotecan to Combination Chemotherapy after Chemoradiation in Patients with Stage II or III Rectal Cancer to Improve the Rate of Complete Response
• 18-399 A Phase II Study of Pembrolizumab Immunotherapy or Placebo after Surgery in Patients with Solid Tumors Containing Certain Genetic Changes

Clinical Trials for Colorectal Cancer